Indonesia’s president receives a Chinese-made vaccine that produced disappointing trial results

  • >>Richard C Paddock and Muktita Suhartono, The New York Times
    Published: 2021-01-13 15:19:01 BdST

bdnews24
An employee at work on Dec.31 2020, at the Global Halal Centre in Bogor, near Jakarta, Indonesia, where the coronavirus vaccine made by the Chinese company Sinovac was analysed to determine the drug’s halal status in Indonesia. The New York Times

Indonesia’s president, Joko Widodo, received an injection of a Chinese-made vaccine on live television Wednesday, as health officials prepared for a nationwide rollout.

Human trials in Indonesia have found that the CoronaVac vaccine was safe and 65.3% effective. But scientists in Brazil said Tuesday that it had an efficacy rate there of just over 50% — far lower than the 78% efficacy rate announced last week.

Joko was the first in Indonesia to get the inoculation, health officials said, because he wanted to assure the public that it was safe, effective and halal, meaning that it is approved under Islamic law.

Behind him as he received his injection was a red sign with white lettering proclaiming the vaccine to be “safe and halal.”

“COVID vaccination is important for us to break the chain of transmission of this coronavirus and provide health protection for all of us, the people of Indonesia, and help accelerate the process of economic recovery,” Joko said after getting his shot.

Indonesia, which authorised emergency use of the Sinovac vaccine Monday, had previously ordered 125.5 million doses from the company and lesser amounts from several others. Indonesia, the world’s fourth-largest country with 270 million people, hopes to achieve herd immunity by vaccinating two-thirds of the population within 15 months.

But there are still questions around the Sinovac vaccine, which China began administering last year before human trials were completed.

The company has yet to release data publicly on the results of its trials. And the vaccine’s efficacy rate, as measured in Brazil and Indonesia, is still far below the 90-plus% rates achieved by the Pfizer and Moderna vaccines that have been approved in the United States and other countries.

Dicky Budiman, an Indonesian epidemiologist at Griffith University in Australia, said the relatively low efficacy rate for CoronaVac should prompt Indonesia to look for alternatives. He also questioned the transparency of the various trials and the data being released.

“At least Indonesia has one vaccine as a tool to protect its health care workers and prevent staff shortages,” he said. “Of course, the government should do its best in getting other vaccines.”

Indonesia plans to give the vaccine first to medical staff, police and soldiers. It also has begun a national promotion campaign to persuade members of the public to get the vaccine, which will be free.

Following Joko to be vaccinated in front of the cameras were the head of the army, the national police chief and the newly appointed health minister, Budi Gunadi Sadikin, along with other dignitaries and so-called influencers.

Indonesia has reported nearly 850,000 coronavirus cases and nearly 25,000 deaths, Southeast Asia’s highest tallies in both categories.

Sulfikar Amir, an Indonesian associate professor of disaster sociology at Nanyang Technological University in Singapore, said Indonesia appeared to be hurrying the vaccine into use rather than doing a better job with social restrictions, testing and tracing.

Brazil’s latest results showing a much lower efficacy rate are cause for concern, he said.

“Why doesn’t Indonesia wait for a better vaccine?” he asked. “The government feels that the situation now is very severe in Indonesia and they look at vaccination as the silver bullet, which actually it is not.”

“My impression,” he added, “is that this is rushed and forced.”

c.2021 The New York Times Company